A new treatment that might one day help all patients with haemophilia, including those that become resistant to existing therapies, has been developed by researchers at the University of Cambridge.
Cambridge spin-out Carrick Therapeutics raises $95 million in funding, representing the largest-ever early stage investment in a UK university spin-out company.
A smart material that switches back and forth between transparent and opaque could be installed in buildings or automobiles, potentially reducing energy bills by avoiding the need for costly air conditioning.
Researchers have built a nano-engine that could form the basis for future applications in nano-robotics, including robots small enough to enter living cells.
For the third consecutive year, the University of Cambridge has broken its early stage investment record, approving 13 seed fund investments for a total of £3.8 million, an increase on the £3.2 million invested in 2013-14.
Three global pharmaceutical companies and the technology transfer offices of three world-leading universities – Imperial College London, University College London and the University of Cambridge – have joined forces with a combined £40 million to create the Apollo Therapeutics Fund.
A new thin-film electrolyte material that helps solid oxide fuel cells operate more efficiently and cheaply than those composed of conventional materials, and has potential applications for portable power sources, has been developed at the University of Cambridge.
A ‘head-up’ display for passenger vehicles developed at Cambridge, the first to incorporate holographic techniques, has been incorporated into Jaguar Land Rover vehicles.
Cambridge Enterprise (CE), the commercialisation arm of the University of Cambridge, has launched a film that showcases some of the world-changing ideas it has supported in the journey to market – from a drug with the potential to save millions of lives to a flower seed mix that helps bees.